Page last updated: 2024-10-15

am336

Description

AM336: calcium channel blocker and antihyperalgesia agent; isolated from the venom of the cone snail, Conus catus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16132255
MeSH IDM0433820

Synonyms (10)

Synonym
leconotide [inn]
247207-64-3
am336
2p1p5jb93s ,
omega-conopeptide cvid
cnsb004
unii-2p1p5jb93s
omega conotoxin cvid
leconotide
DTXSID30179455

Toxicity

ExcerptReference
" Doses in a range up to maximum no side effect doses were tested for antihyperalgesic effects in rats with hyperalgesia."( CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain.
Cooke, I; Goodchild, CS; Kolosov, A, 2010
)
"The maximum no side effect dose of leconotide (2 mg/kg intravenously) caused 51."( CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain.
Cooke, I; Goodchild, CS; Kolosov, A, 2010
)

Dosage Studied

ExcerptReference
") bolus dosing in rats with adjuvant-induced chronic inflammatory pain of the right hindpaw and to (ii) quantify the inhibitory effects of AM336 relative to MVIIA on K+-evoked SP release from slices of rat spinal cord."( The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices.
Cabot, PJ; Lewis, RJ; Robertson, AD; Ross, FB; Smith, MT, 2002
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (58.33)29.6817
2010's5 (41.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]